Marianne de Backer - 22 Feb 2024 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role: Chief Executive Officer, Director
Signature: /s/ Sung Lee, Attorney-in-Fact
Issuer symbol: VIR
Transactions as of: 22 Feb 2024
Net transactions value: $0
Form type: 4
Filing time: 26 Feb 2024, 19:32:59 UTC
Previous filing: 26 Jun 2023
Next filing: 04 Apr 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	VIR	Common Stock	Award	$0	+175,000	+30%	$0.000000	751,452	22 Feb 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	VIR	Stock Option (Right to Buy)	Award	$0	+350,000		$0.000000	350,000	22 Feb 2024	Common Stock	350,000	$10.11	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan.
F2	25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter.